{"id":"W2964353176","doi":"10.1200/jco.2012.30.15_suppl.tps6640","title":"An open-label, multicenter, expanded access study assessing the safety and efficacy of oral ruxolitinib administered to patients with primary myelofibrosis (PMF), post-polycythemia myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ruxolitinib; Myelofibrosis; Essential thrombocythemia; Internal medicine; Polycythemia vera; Clinical endpoint; Constitutional symptoms; Anemia; International Prognostic Scoring System; Gastroenterology; Phases of clinical research; Bone marrow; Clinical trial; Myelodysplastic syndromes; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002251563,0.001512093,0.002109564,0.0003594682,0.000536532,0.0009417058,0.0007065473,0.001617875,0.006904482],"category_scores_gemma":[0.001818404,0.0005994487,0.001097004,0.0004326102,0.001071063,0.001408478,0.0004970379,0.002783392,0.001312296],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007236231,"about_ca_system_score_gemma":0.001395509,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006522664,"about_ca_topic_score_gemma":0.001268496,"domain_scores_codex":[0.9992524,0.0003729103,0.00004027706,0.000157829,0.00006955351,0.0001070023],"domain_scores_gemma":[0.9979554,0.0003522474,0.0004324461,0.0001887224,0.0001329784,0.0009381827],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9301057,0.0344464,0.008408234,0.0003337975,0.0008239064,0.0001530763,0.000126517,0.0004387593,0.006102496,0.0000900751,0.001276517,0.01769446],"study_design_scores_gemma":[0.6603284,0.3158869,0.02059292,0.00002316225,0.0004308333,0.0001678096,0.00004228697,0.0004509232,0.0007301769,0.00009813298,0.001224153,0.00002424241],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9915733,0.0007984129,0.0004137627,0.0002128223,0.00008598749,0.003150612,0.00225085,0.00005998156,0.001454366],"genre_scores_gemma":[0.9880867,0.0004884142,0.0009572936,0.000719855,0.0002560473,0.003566609,0.003836527,0.00001892597,0.002069628],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006904482,"threshold_uncertainty_score":0.02309781,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1290682232802112,"score_gpt":0.4904048516542319,"score_spread":0.3613366283740207,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}